Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAG72-CAR T cells in Advanced Epithelial Ovarian Cancer
NCT05225363Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Nov 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAG-72 CAR-T cells in Epithelial Ovarian Cancer (EOC), sponsored by City of Hope. Primary endpoints: Incidence of dose limiting toxicities up to 28 days and Incidence of adverse events. Started May 2023; status: recruiting.
02
Drugs
TAG-72 CAR-T cells
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT05225363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225363.